-
1
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials
-
Early Breast Cancer Trialists' Collaborative Group
-
Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
2
-
-
74849135474
-
Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization
-
10.1007/s10549-009-0433-y, 19526354
-
Sparano JA, Hortobagyi GN, Gralow JR, Perez EA, Comis RL. Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Res Treat 2010, 119:511-527. 10.1007/s10549-009-0433-y, 19526354.
-
(2010)
Breast Cancer Res Treat
, vol.119
, pp. 511-527
-
-
Sparano, J.A.1
Hortobagyi, G.N.2
Gralow, J.R.3
Perez, E.A.4
Comis, R.L.5
-
3
-
-
76849087811
-
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
-
10.1038/nrclinonc.2009.186, 19997076
-
Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010, 7:22-36. 10.1038/nrclinonc.2009.186, 19997076.
-
(2010)
Nat Rev Clin Oncol
, vol.7
, pp. 22-36
-
-
Bedard, P.L.1
Di Leo, A.2
Piccart-Gebhart, M.J.3
-
4
-
-
0036098442
-
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial
-
Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002, 8:1073-1079.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1073-1079
-
-
Buzdar, A.U.1
Singletary, S.E.2
Valero, V.3
Booser, D.J.4
Ibrahim, N.K.5
Rahman, Z.6
Theriault, R.L.7
Walters, R.8
Rivera, E.9
Smith, T.L.10
Holmes, F.A.11
Hoy, E.12
Frye, D.K.13
Manuel, N.14
Kau, S.W.15
McNeese, M.D.16
Strom, E.17
Thomas, E.18
Hunt, K.19
Ames, F.20
Berry, D.21
Hortobagyi, G.N.22
more..
-
5
-
-
0037445132
-
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
-
10.1200/JCO.2003.02.063, 12637460
-
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983. 10.1200/JCO.2003.02.063, 12637460.
-
(2003)
J Clin Oncol
, vol.21
, pp. 976-983
-
-
Henderson, I.C.1
Berry, D.A.2
Demetri, G.D.3
Cirrincione, C.T.4
Goldstein, L.J.5
Martino, S.6
Ingle, J.N.7
Cooper, M.R.8
Hayes, D.F.9
Tkaczuk, K.H.10
Fleming, G.11
Holland, J.F.12
Duggan, D.B.13
Carpenter, J.T.14
Frei, E.15
Schilsky, R.L.16
Wood, W.C.17
Muss, H.B.18
Norton, L.19
-
6
-
-
20544434991
-
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28
-
10.1200/JCO.2005.10.517, 15897552
-
Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696. 10.1200/JCO.2005.10.517, 15897552.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3686-3696
-
-
Mamounas, E.P.1
Bryant, J.2
Lembersky, B.3
Fehrenbacher, L.4
Sedlacek, S.M.5
Fisher, B.6
Wickerham, D.L.7
Yothers, G.8
Soran, A.9
Wolmark, N.10
-
7
-
-
21144435932
-
Adjuvant docetaxel for node-positive breast cancer
-
10.1056/NEJMoa043681, 15930421
-
Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313. 10.1056/NEJMoa043681, 15930421.
-
(2005)
N Engl J Med
, vol.352
, pp. 2302-2313
-
-
Martin, M.1
Pienkowski, T.2
Mackey, J.3
Pawlicki, M.4
Guastalla, J.P.5
Weaver, C.6
Tomiak, E.7
Al-Tweigeri, T.8
Chap, L.9
Juhos, E.10
Guevin, R.11
Howell, A.12
Fornander, T.13
Hainsworth, J.14
Coleman, R.15
Vinholes, J.16
Modiano, M.17
Pinter, T.18
Tang, S.C.19
Colwell, B.20
Prady, C.21
Provencher, L.22
Walde, D.23
Rodriguez-Lescure, A.24
Hugh, J.25
Loret, C.26
Rupin, M.27
Blitz, S.28
Jacobs, P.29
Murawsky, M.30
more..
-
8
-
-
34247329446
-
Sequential adjuvant Epirubicin-based and Docetaxel Chemotherapy for node-positive breast cancer patients: the PACS01 trial
-
10.1200/JCO.2006.07.3916, 17116941
-
Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Sequential adjuvant Epirubicin-based and Docetaxel Chemotherapy for node-positive breast cancer patients: the PACS01 trial. J Clin Oncol 2006, 24:5664-5671. 10.1200/JCO.2006.07.3916, 17116941.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5664-5671
-
-
Roche, H.1
Fumoleau, P.2
Spielmann, M.3
Canon, J.L.4
Delozier, T.5
Serin, D.6
Symann, M.7
Kerbrat, P.8
Soulié, P.9
Eichler, F.10
Viens, P.11
Monnier, A.12
Vindevoghel, A.13
Campone, M.14
Goudier, M.J.15
Bonneterre, J.16
Ferrero, J.M.17
Martin, A.L.18
Genève, J.19
Asselain, B.20
more..
-
9
-
-
65549146500
-
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
-
10.1016/S0140-6736(09)60740-6, 2687939, 19447249
-
Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009, 373:1681-1692. 10.1016/S0140-6736(09)60740-6, 2687939, 19447249.
-
(2009)
Lancet
, vol.373
, pp. 1681-1692
-
-
Ellis, P.1
Barrett-Lee, P.2
Johnson, L.3
Cameron, D.4
Wardley, A.5
O'Reilly, S.6
Verrill, M.7
Smith, I.8
Yarnold, J.9
Coleman, R.10
Earl, H.11
Canney, P.12
Twelves, C.13
Poole, C.14
Bloomfield, D.15
Hopwood, P.16
Johnston, S.17
Dowsett, M.18
Bartlett, J.M.19
Ellis, I.20
Peckitt, C.21
Hall, E.22
Bliss, J.M.23
more..
-
10
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
10.1056/NEJMoa053028, 16495393
-
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820. 10.1056/NEJMoa053028, 16495393.
-
(2006)
N Engl J Med
, vol.354
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.L.2
Bono, P.3
Alanko, T.4
Kataja, V.5
Asola, R.6
Utriainen, T.7
Kokko, R.8
Hemminki, A.9
Tarkkanen, M.10
Turpeenniemi-Hujanen, T.11
Jyrkkio, S.12
Flander, M.13
Helle, L.14
Ingalsuo, S.15
Johansson, K.16
Jaaskelainen, A.S.17
Pajunen, M.18
Rauhala, M.19
Kaleva-Kerola, J.20
Salminen, T.21
Leinonen, M.22
Elomaa, I.23
Isola, J.24
more..
-
11
-
-
73949090093
-
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer
-
2799234, 19901117
-
Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O''Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 2009, 28:77-82. 2799234, 19901117.
-
(2009)
J Clin Oncol
, vol.28
, pp. 77-82
-
-
Burnell, M.1
Levine, M.N.2
Chapman, J.A.3
Bramwell, V.4
Gelmon, K.5
Walley, B.6
Vandenberg, T.7
Chalchal, H.8
Albain, K.S.9
Perez, E.A.10
Rugo, H.11
Pritchard, K.12
O'Brien, P.13
Shepherd, L.E.14
-
12
-
-
21144439271
-
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study
-
10.1200/JCO.2005.06.156, 15860854
-
Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Mansi JL. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 2005, 23:2988-2995. 10.1200/JCO.2005.06.156, 15860854.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2988-2995
-
-
Evans, T.R.1
Yellowlees, A.2
Foster, E.3
Earl, H.4
Cameron, D.A.5
Hutcheon, A.W.6
Coleman, R.E.7
Perren, T.8
Gallagher, C.J.9
Quigley, M.10
Crown, J.11
Jones, A.L.12
Highley, M.13
Leonard, R.C.14
Mansi, J.L.15
-
13
-
-
27744538443
-
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
-
10.1093/annonc/mdi366, 16148021
-
Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, Siafaka V, Kosmidis P, Timotheadou E, Tsavdaridis D, Bafaloukos D, Papakostas P, Razis E, Makrantonakis P, Aravantinos G, Christodoulou C, Dimopoulos AM. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005, 16:1762-1771. 10.1093/annonc/mdi366, 16148021.
-
(2005)
Ann Oncol
, vol.16
, pp. 1762-1771
-
-
Fountzilas, G.1
Skarlos, D.2
Dafni, U.3
Gogas, H.4
Briasoulis, E.5
Pectasides, D.6
Papadimitriou, C.7
Markopoulos, C.8
Polychronis, A.9
Kalofonos, H.P.10
Siafaka, V.11
Kosmidis, P.12
Timotheadou, E.13
Tsavdaridis, D.14
Bafaloukos, D.15
Papakostas, P.16
Razis, E.17
Makrantonakis, P.18
Aravantinos, G.19
Christodoulou, C.20
Dimopoulos, A.M.21
more..
-
14
-
-
38449108413
-
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial
-
10.1093/jnci/djm287, 18182617
-
Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjold B, Lang I, Jakesz R, Vorobiof D, Gutierrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008, 100:121-133. 10.1093/jnci/djm287, 18182617.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 121-133
-
-
Francis, P.1
Crown, J.2
Di Leo, A.3
Buyse, M.4
Balil, A.5
Andersson, M.6
Nordenskjold, B.7
Lang, I.8
Jakesz, R.9
Vorobiof, D.10
Gutierrez, J.11
van Hazel, G.12
Dolci, S.13
Jamin, S.14
Bendahmane, B.15
Gelber, R.D.16
Goldhirsch, A.17
Castiglione-Gertsch, M.18
Piccart-Gebhart, M.19
-
15
-
-
66349089054
-
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
-
10.1200/JCO.2008.19.2567, 19332727
-
Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009, 27:2474-2481. 10.1200/JCO.2008.19.2567, 19332727.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2474-2481
-
-
Gianni, L.1
Baselga, J.2
Eiermann, W.3
Porta, V.G.4
Semiglazov, V.5
Lluch, A.6
Zambetti, M.7
Sabadell, D.8
Raab, G.9
Cussac, A.L.10
Bozhok, A.11
Martinez-Agullo, A.12
Greco, M.13
Byakhov, M.14
Lopez, J.J.15
Mansutti, M.16
Valagussa, P.17
Bonadonna, G.18
-
16
-
-
62449193617
-
Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735
-
10.1200/JCO.2008.18.4028, 19204201
-
Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009, 27:1177-1183. 10.1200/JCO.2008.18.4028, 19204201.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1177-1183
-
-
Jones, S.1
Holmes, F.A.2
O'Shaughnessy, J.3
Blum, J.L.4
Vukelja, S.J.5
McIntyre, K.J.6
Pippen, J.E.7
Bordelon, J.H.8
Kirby, R.L.9
Sandbach, J.10
Hyman, W.J.11
Richards, D.A.12
Mennel, R.G.13
Boehm, K.A.14
Meyer, W.G.15
Asmar, L.16
Mackey, D.17
Riedel, S.18
Muss, H.19
Savin, M.A.20
more..
-
17
-
-
51749093141
-
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
-
10.1200/JCO.2008.16.7841, 2654376, 18678836
-
Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008, 26:4092-4099. 10.1200/JCO.2008.16.7841, 2654376, 18678836.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4092-4099
-
-
Goldstein, L.J.1
O'Neill, A.2
Sparano, J.A.3
Perez, E.A.4
Shulman, L.N.5
Martino, S.6
Davidson, N.E.7
-
18
-
-
44949228316
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer
-
10.1093/jnci/djn151, 18505968
-
Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, de Alava E, Lopez Garcia-Asenjo JA, Guitian MD, Almenar S, Gonzalez-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Segui MA, Mayordomo JI, Anton A, Baena JM, Plazaola A, Modolell A, Pelegri A, Mel JR, Aranda E, Adrover E, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008, 100:805-814. 10.1093/jnci/djn151, 18505968.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 805-814
-
-
Martin, M.1
Rodriguez-Lescure, A.2
Ruiz, A.3
Alba, E.4
Calvo, L.5
Ruiz-Borrego, M.6
Munarriz, B.7
Rodriguez, C.A.8
Crespo, C.9
de Alava, E.10
Lopez Garcia-Asenjo, J.A.11
Guitian, M.D.12
Almenar, S.13
Gonzalez-Palacios, J.F.14
Vera, F.15
Palacios, J.16
Ramos, M.17
Gracia Marco, J.M.18
Lluch, A.19
Alvarez, I.20
Segui, M.A.21
Mayordomo, J.I.22
Anton, A.23
Baena, J.M.24
Plazaola, A.25
Modolell, A.26
Pelegri, A.27
Mel, J.R.28
Aranda, E.29
Adrover, E.30
more..
-
19
-
-
72449138560
-
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
-
10.1007/s10549-009-0468-0, 19636702
-
Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 2010, 119:95-104. 10.1007/s10549-009-0468-0, 19636702.
-
(2010)
Breast Cancer Res Treat
, vol.119
, pp. 95-104
-
-
Polyzos, A.1
Malamos, N.2
Boukovinas, I.3
Adamou, A.4
Ziras, N.5
Kalbakis, K.6
Kakolyris, S.7
Syrigos, K.8
Papakotoulas, P.9
Kouroussis, C.10
Karvounis, N.11
Vamvakas, L.12
Christophyllakis, C.13
Athanasiadis, A.14
Varthalitis, I.15
Georgoulias, V.16
Mavroudis, D.17
-
20
-
-
84868107005
-
Sequential epirubicin-docetaxel-CMF as adjuvant therapy for node-positive early breast cancer: updated results of the TAXIt216 randomized trial
-
Cognetti F, De Laurentiis M, De Matteis A, Manzione L, Boni C, Palazzo S, Di Palma M, Papaldo P, De Placido S, Bianco AR. Sequential epirubicin-docetaxel-CMF as adjuvant therapy for node-positive early breast cancer: updated results of the TAXIt216 randomized trial. Ann Oncol 2008, 19:a1820.
-
(2008)
Ann Oncol
, vol.19
-
-
Cognetti, F.1
De Laurentiis, M.2
De Matteis, A.3
Manzione, L.4
Boni, C.5
Palazzo, S.6
Di Palma, M.7
Papaldo, P.8
De Placido, S.9
Bianco, A.R.10
-
21
-
-
76849117354
-
Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group
-
Intergruppo GONO-M
-
Del Mastro L, Costantini M, Durando A, Michelotti A, Danese S, Aitini E, Olmeo N, Pronzato P, Venturini M, . Intergruppo GONO-M Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group. J Clin Oncol 2008, 26:a516. Intergruppo GONO-M.
-
(2008)
J Clin Oncol
, vol.26
-
-
Del Mastro, L.1
Costantini, M.2
Durando, A.3
Michelotti, A.4
Danese, S.5
Aitini, E.6
Olmeo, N.7
Pronzato, P.8
Venturini, M.9
-
22
-
-
76849098541
-
Interim results of Intergroup EC-Doc Trial: a randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1-3 positive lymph nodes [abstract]
-
West German Study Group/AGO-Mamma
-
Nitz U, Huober JB, Lisboa B, Harbeck N, Fischer H, Moebus V, Hoffmann G, Augustin D, Weiss E, Kuhn W, . West German Study Group/AGO-Mamma Interim results of Intergroup EC-Doc Trial: a randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1-3 positive lymph nodes [abstract]. J Clin Oncol 2008, 26:a515. West German Study Group/AGO-Mamma.
-
(2008)
J Clin Oncol
, vol.26
-
-
Nitz, U.1
Huober, J.B.2
Lisboa, B.3
Harbeck, N.4
Fischer, H.5
Moebus, V.6
Hoffmann, G.7
Augustin, D.8
Weiss, E.9
Kuhn, W.10
-
23
-
-
33646873043
-
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients
-
10.1002/cncr.21886, 16649217
-
Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F, Giannarelli D. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006, 106:2337-2344. 10.1002/cncr.21886, 16649217.
-
(2006)
Cancer
, vol.106
, pp. 2337-2344
-
-
Bria, E.1
Nistico, C.2
Cuppone, F.3
Carlini, P.4
Ciccarese, M.5
Milella, M.6
Natoli, G.7
Terzoli, E.8
Cognetti, F.9
Giannarelli, D.10
-
24
-
-
37849035252
-
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
-
10.1200/JCO.2007.11.3787, 18165639
-
De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008, 26:44-53. 10.1200/JCO.2007.11.3787, 18165639.
-
(2008)
J Clin Oncol
, vol.26
, pp. 44-53
-
-
De Laurentiis, M.1
Cancello, G.2
D''Agostino, D.3
Giuliano, M.4
Giordano, A.5
Montagna, E.6
Lauria, R.7
Forestieri, V.8
Esposito, A.9
Silvestro, L.10
Pennacchio, R.11
Criscitiello, C.12
Montanino, A.13
Limite, G.14
Bianco, A.R.15
De Placido, S.16
-
25
-
-
44949169685
-
Taxanes for adjuvant treatment of early breast cancer
-
Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007, CD004421.
-
(2007)
Cochrane Database Syst Rev
-
-
Ferguson, T.1
Wilcken, N.2
Vagg, R.3
Ghersi, D.4
Nowak, A.K.5
-
26
-
-
33745696736
-
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
-
10.1093/annonc/mdl135, 16766587
-
Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, Rodriguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacon C, Roset M, Anton A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, Lopez-Vega JM, Munoz M, Mel JR. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006, 17:1205-1212. 10.1093/annonc/mdl135, 16766587.
-
(2006)
Ann Oncol
, vol.17
, pp. 1205-1212
-
-
Martin, M.1
Lluch, A.2
Segui, M.A.3
Ruiz, A.4
Ramos, M.5
Adrover, E.6
Rodriguez-Lescure, A.7
Grosse, R.8
Calvo, L.9
Fernandez-Chacon, C.10
Roset, M.11
Anton, A.12
Isla, D.13
del Prado, P.M.14
Iglesias, L.15
Zaluski, J.16
Arcusa, A.17
Lopez-Vega, J.M.18
Munoz, M.19
Mel, J.R.20
more..
-
27
-
-
45749149210
-
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis
-
10.1200/JCO.2007.14.9146, 18509176
-
Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 2008, 26:2636-2643. 10.1200/JCO.2007.14.9146, 18509176.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2636-2643
-
-
Andre, F.1
Broglio, K.2
Roche, H.3
Martin, M.4
Mackey, J.R.5
Penault-Llorca, F.6
Hortobagyi, G.N.7
Pusztai, L.8
-
28
-
-
35248895346
-
HER2 and response to paclitaxel in node-positive breast cancer
-
10.1056/NEJMoa071167, 17928597
-
Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357:1496-1506. 10.1056/NEJMoa071167, 17928597.
-
(2007)
N Engl J Med
, vol.357
, pp. 1496-1506
-
-
Hayes, D.F.1
Thor, A.D.2
Dressler, L.G.3
Weaver, D.4
Edgerton, S.5
Cowan, D.6
Broadwater, G.7
Goldstein, L.J.8
Martino, S.9
Ingle, J.N.10
Henderson, I.C.11
Norton, L.12
Winer, E.P.13
Hudis, C.A.14
Ellis, M.J.15
Berry, D.A.16
-
29
-
-
62549091454
-
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial
-
10.1200/JCO.2008.18.1024, 2667821, 19204205
-
Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-1176. 10.1200/JCO.2008.18.1024, 2667821, 19204205.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1168-1176
-
-
Hugh, J.1
Hanson, J.2
Cheang, M.C.3
Nielsen, T.O.4
Perou, C.M.5
Dumontet, C.6
Reed, J.7
Krajewska, M.8
Treilleux, I.9
Rupin, M.10
Magherini, E.11
Mackey, J.12
Martin, M.13
Vogel, C.14
-
30
-
-
67649983962
-
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer
-
10.1200/JCO.2008.18.2808, 19380452
-
Penault-Llorca F, Andre F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roche H. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2809-2815. 10.1200/JCO.2008.18.2808, 19380452.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2809-2815
-
-
Penault-Llorca, F.1
Andre, F.2
Sagan, C.3
Lacroix-Triki, M.4
Denoux, Y.5
Verriele, V.6
Jacquemier, J.7
Baranzelli, M.C.8
Bibeau, F.9
Antoine, M.10
Lagarde, N.11
Martin, A.L.12
Asselain, B.13
Roche, H.14
-
31
-
-
77955774645
-
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
-
10.1007/s10549-009-0663-z, 20037779
-
Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodriguez CA, Crespo C, Abad M, Dominguez S, Florian J, Llorca C, Mendez M, Godes M, Cubedo R, Murias A, Batista N, Garcia MJ, Caballero R, de Alava E. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010, 123:149-157. 10.1007/s10549-009-0663-z, 20037779.
-
(2010)
Breast Cancer Res Treat
, vol.123
, pp. 149-157
-
-
Martin, M.1
Rodriguez-Lescure, A.2
Ruiz, A.3
Alba, E.4
Calvo, L.5
Ruiz-Borrego, M.6
Santaballa, A.7
Rodriguez, C.A.8
Crespo, C.9
Abad, M.10
Dominguez, S.11
Florian, J.12
Llorca, C.13
Mendez, M.14
Godes, M.15
Cubedo, R.16
Murias, A.17
Batista, N.18
Garcia, M.J.19
Caballero, R.20
de Alava, E.21
more..
-
32
-
-
77955097761
-
BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy
-
10.1158/1078-0432.CCR-10-0079, 20576719
-
Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechere L, Reed JC. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 2010, 16:3988-3997. 10.1158/1078-0432.CCR-10-0079, 20576719.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3988-3997
-
-
Dumontet, C.1
Krajewska, M.2
Treilleux, I.3
Mackey, J.R.4
Martin, M.5
Rupin, M.6
Lafanechere, L.7
Reed, J.C.8
-
33
-
-
13444249484
-
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis
-
Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005, 65:767-779.
-
(2005)
Cancer Res
, vol.65
, pp. 767-779
-
-
Jacquemier, J.1
Ginestier, C.2
Rougemont, J.3
Bardou, V.J.4
Charafe-Jauffret, E.5
Geneix, J.6
Adelaide, J.7
Koki, A.8
Houvenaeghel, G.9
Hassoun, J.10
Maraninchi, D.11
Viens, P.12
Birnbaum, D.13
Bertucci, F.14
-
34
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
10.1073/pnas.191367098, 58566, 11553815
-
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 10869-10874
-
-
Sorlie, T.1
Perou, C.M.2
Tibshirani, R.3
Aas, T.4
Geisler, S.5
Johnsen, H.6
Hastie, T.7
Eisen, M.B.8
van de Rijn, M.9
Jeffrey, S.S.10
Thorsen, T.11
Quist, H.12
Matese, J.C.13
Brown, P.O.14
Botstein, D.15
Eystein Lonning, P.16
Borresen-Dale, A.L.17
-
35
-
-
34248595234
-
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
-
10.1038/sj.bjc.6603756, 2359936, 17453008
-
de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96:1504-1513. 10.1038/sj.bjc.6603756, 2359936, 17453008.
-
(2007)
Br J Cancer
, vol.96
, pp. 1504-1513
-
-
de Azambuja, E.1
Cardoso, F.2
de Castro, G.3
Colozza, M.4
Mano, M.S.5
Durbecq, V.6
Sotiriou, C.7
Larsimont, D.8
Piccart-Gebhart, M.J.9
Paesmans, M.10
-
36
-
-
48849096940
-
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients
-
10.1016/j.breast.2008.02.002, 18455396
-
Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17:323-334. 10.1016/j.breast.2008.02.002, 18455396.
-
(2008)
Breast
, vol.17
, pp. 323-334
-
-
Stuart-Harris, R.1
Caldas, C.2
Pinder, S.E.3
Pharoah, P.4
-
37
-
-
39749161389
-
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients
-
10.1007/s10549-007-9590-z, 17468949
-
Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K, Mohsin S, Gray T, Alvarez L, Chamness GC, Osborne CK, Shak S. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 2008, 108:233-240. 10.1007/s10549-007-9590-z, 17468949.
-
(2008)
Breast Cancer Res Treat
, vol.108
, pp. 233-240
-
-
Chang, J.C.1
Makris, A.2
Gutierrez, M.C.3
Hilsenbeck, S.G.4
Hackett, J.R.5
Jeong, J.6
Liu, M.L.7
Baker, J.8
Clark-Langone, K.9
Baehner, F.L.10
Sexton, K.11
Mohsin, S.12
Gray, T.13
Alvarez, L.14
Chamness, G.C.15
Osborne, C.K.16
Shak, S.17
-
38
-
-
75149128222
-
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
-
10.1186/bcr2363, 2790846, 19758440
-
Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M, Schluns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009, 11:R69. 10.1186/bcr2363, 2790846, 19758440.
-
(2009)
Breast Cancer Res
, vol.11
-
-
Darb-Esfahani, S.1
Loibl, S.2
Muller, B.M.3
Roller, M.4
Denkert, C.5
Komor, M.6
Schluns, K.7
Blohmer, J.U.8
Budczies, J.9
Gerber, B.10
Noske, A.11
du Bois, A.12
Weichert, W.13
Jackisch, C.14
Dietel, M.15
Richter, K.16
Kaufmann, M.17
von Minckwitz, G.18
-
39
-
-
0037314676
-
Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study
-
Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003, 9:686-692.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 686-692
-
-
Estevez, L.G.1
Cuevas, J.M.2
Anton, A.3
Florian, J.4
Lopez-Vega, J.M.5
Velasco, A.6
Lobo, F.7
Herrero, A.8
Fortes, J.9
-
40
-
-
0343517136
-
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
-
Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000, 6:3103-3110.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3103-3110
-
-
Sjostrom, J.1
Blomqvist, C.2
Heikkila, P.3
Boguslawski, K.V.4
Raisanen-Sokolowski, A.5
Bengtsson, N.O.6
Mjaaland, I.7
Malmstrom, P.8
Ostenstadt, B.9
Bergh, J.10
Wist, E.11
Valvere, V.12
Saksela, E.13
-
41
-
-
33744814477
-
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
-
10.1200/JCO.2005.04.7985, 16720680
-
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734. 10.1200/JCO.2005.04.7985, 16720680.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3726-3734
-
-
Paik, S.1
Tang, G.2
Shak, S.3
Kim, C.4
Baker, J.5
Kim, W.6
Cronin, M.7
Baehner, F.L.8
Watson, D.9
Bryant, J.10
Costantino, J.P.11
Geyer, C.E.12
Wickerham, D.L.13
Wolmark, N.14
-
42
-
-
39149102890
-
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
-
10.1093/jnci/djm289, 18230798
-
Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008, 100:207-212. 10.1093/jnci/djm289, 18230798.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 207-212
-
-
Viale, G.1
Regan, M.M.2
Mastropasqua, M.G.3
Maffini, F.4
Maiorano, E.5
Colleoni, M.6
Price, K.N.7
Golouh, R.8
Perin, T.9
Brown, R.W.10
Kovacs, A.11
Pillay, K.12
Ohlschlegel, C.13
Gusterson, B.A.14
Castiglione-Gertsch, M.15
Gelber, R.D.16
Goldhirsch, A.17
Coates, A.S.18
-
43
-
-
77349118709
-
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
-
10.1016/S1470-2045(10)70006-1, 20079691
-
Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 2010, 11:266-274. 10.1016/S1470-2045(10)70006-1, 20079691.
-
(2010)
Lancet Oncol
, vol.11
, pp. 266-274
-
-
Bartlett, J.M.1
Munro, A.F.2
Dunn, J.A.3
McConkey, C.4
Jordan, S.5
Twelves, C.J.6
Cameron, D.A.7
Thomas, J.8
Campbell, F.M.9
Rea, D.W.10
Provenzano, E.11
Caldas, C.12
Pharoah, P.13
Hiller, L.14
Earl, H.15
Poole, C.J.16
-
44
-
-
20544434991
-
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28
-
10.1200/JCO.2005.10.517, 15897552
-
Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696. 10.1200/JCO.2005.10.517, 15897552.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3686-3696
-
-
Mamounas, E.P.1
Bryant, J.2
Lembersky, B.3
Fehrenbacher, L.4
Sedlacek, S.M.5
Fisher, B.6
Wickerham, D.L.7
Yothers, G.8
Soran, A.9
Wolmark, N.10
-
45
-
-
33645729203
-
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
-
10.1001/jama.295.14.1658, 1459540, 16609087
-
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667. 10.1001/jama.295.14.1658, 1459540, 16609087.
-
(2006)
JAMA
, vol.295
, pp. 1658-1667
-
-
Berry, D.A.1
Cirrincione, C.2
Henderson, I.C.3
Citron, M.L.4
Budman, D.R.5
Goldstein, L.J.6
Martino, S.7
Perez, E.A.8
Muss, H.B.9
Norton, L.10
Hudis, C.11
Winer, E.P.12
-
46
-
-
33645727496
-
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
-
10.1007/s10549-005-9062-2, 16538542
-
Kostopoulos I, Arapantoni-Dadioti P, Gogas H, Papadopoulos S, Malamou-Mitsi V, Scopa CD, Markaki S, Karagianni E, Kyriakou V, Margariti A, Kyrkou E, Pavlakis K, Zaramboukas T, Skordalaki A, Bourli A, Markopoulos C, Pectasides D, Dimopoulos MA, Skarlos D, Fountzilas G. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat 2006, 96:251-261. 10.1007/s10549-005-9062-2, 16538542.
-
(2006)
Breast Cancer Res Treat
, vol.96
, pp. 251-261
-
-
Kostopoulos, I.1
Arapantoni-Dadioti, P.2
Gogas, H.3
Papadopoulos, S.4
Malamou-Mitsi, V.5
Scopa, C.D.6
Markaki, S.7
Karagianni, E.8
Kyriakou, V.9
Margariti, A.10
Kyrkou, E.11
Pavlakis, K.12
Zaramboukas, T.13
Skordalaki, A.14
Bourli, A.15
Markopoulos, C.16
Pectasides, D.17
Dimopoulos, M.A.18
Skarlos, D.19
Fountzilas, G.20
more..
-
47
-
-
71749084050
-
Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?
-
Hayes DF. Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?. Breast 2009, 18:S131-134.
-
(2009)
Breast
, vol.18
-
-
Hayes, D.F.1
-
48
-
-
34247508923
-
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
-
10.1158/1078-0432.CCR-06-2078, 17404087
-
Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007, 13:2061-2067. 10.1158/1078-0432.CCR-06-2078, 17404087.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2061-2067
-
-
Andre, F.1
Hatzis, C.2
Anderson, K.3
Sotiriou, C.4
Mazouni, C.5
Mejia, J.6
Wang, B.7
Hortobagyi, G.N.8
Symmans, W.F.9
Pusztai, L.10
-
49
-
-
33746604292
-
Predictive factors for response to docetaxel in human breast cancers
-
10.1111/j.1349-7006.2006.00265.x, 16805818
-
Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006, 97:813-820. 10.1111/j.1349-7006.2006.00265.x, 16805818.
-
(2006)
Cancer Sci
, vol.97
, pp. 813-820
-
-
Noguchi, S.1
-
50
-
-
0029956081
-
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
-
10.1038/nm0796-811, 8673929
-
Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2:811-814. 10.1038/nm0796-811, 8673929.
-
(1996)
Nat Med
, vol.2
, pp. 811-814
-
-
Aas, T.1
Borresen, A.L.2
Geisler, S.3
Smith-Sorensen, B.4
Johnsen, H.5
Varhaug, J.E.6
Akslen, L.A.7
Lonning, P.E.8
-
51
-
-
0030026934
-
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
-
10.1038/nm0196-72, 8564846
-
Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2:72-79. 10.1038/nm0196-72, 8564846.
-
(1996)
Nat Med
, vol.2
, pp. 72-79
-
-
Wahl, A.F.1
Donaldson, K.L.2
Fairchild, C.3
Lee, F.Y.4
Foster, S.A.5
Demers, G.W.6
Galloway, D.A.7
-
52
-
-
77951925779
-
Gene expression profiling of breast cancer
-
Pusztai L. Gene expression profiling of breast cancer. Breast Cancer Res 2009, 11:S11.
-
(2009)
Breast Cancer Res
, vol.11
-
-
Pusztai, L.1
-
53
-
-
79960980007
-
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
-
10.1093/annonc/mdr304, 3144634, 21709140
-
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747. 10.1093/annonc/mdr304, 3144634, 21709140.
-
(2011)
Ann Oncol
, vol.22
, pp. 1736-1747
-
-
Goldhirsch, A.1
Wood, W.C.2
Coates, A.S.3
Gelber, R.D.4
Thurlimann, B.5
Senn, H.J.6
-
54
-
-
66849140730
-
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
-
10.1093/jnci/djp082, 2684553, 19436038
-
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 736-750
-
-
Cheang, M.C.1
Chia, S.K.2
Voduc, D.3
Gao, D.4
Leung, S.5
Snider, J.6
Watson, M.7
Davies, S.8
Bernard, P.S.9
Parker, J.S.10
Perou, C.M.11
Ellis, M.J.12
Nielsen, T.O.13
-
55
-
-
27244443082
-
Proliferation marker Ki-67 in early breast cancer
-
10.1200/JCO.2005.07.501, 16192605
-
Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23:7212-7220. 10.1200/JCO.2005.07.501, 16192605.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7212-7220
-
-
Urruticoechea, A.1
Smith, I.E.2
Dowsett, M.3
-
56
-
-
57149103724
-
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
-
10.1200/JCO.2008.17.0829, 2651094, 18981464
-
Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thurlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008, 26:5569-5575. 10.1200/JCO.2008.17.0829, 2651094, 18981464.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5569-5575
-
-
Viale, G.1
Giobbie-Hurder, A.2
Regan, M.M.3
Coates, A.S.4
Mastropasqua, M.G.5
Dell'Orto, P.6
Maiorano, E.7
MacGrogan, G.8
Braye, S.G.9
Ohlschlegel, C.10
Neven, P.11
Orosz, Z.12
Olszewski, W.P.13
Knox, F.14
Thurlimann, B.15
Price, K.N.16
Castiglione-Gertsch, M.17
Gelber, R.D.18
Gusterson, B.A.19
Goldhirsch, A.20
more..
-
57
-
-
75249083420
-
Ki67 in breast cancer: prognostic and predictive potential
-
10.1016/S1470-2045(09)70262-1, 20152769
-
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11:174-183. 10.1016/S1470-2045(09)70262-1, 20152769.
-
(2010)
Lancet Oncol
, vol.11
, pp. 174-183
-
-
Yerushalmi, R.1
Woods, R.2
Ravdin, P.M.3
Hayes, M.M.4
Gelmon, K.A.5
-
58
-
-
0034668136
-
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data
-
10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M, 10986536
-
Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000, 19:2595-2609. 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M, 10986536.
-
(2000)
Stat Med
, vol.19
, pp. 2595-2609
-
-
Bonetti, M.1
Gelber, R.D.2
|